Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials

Disease etiology, baseline factors (NYHA FC, PVRI and SVO2) and on-treatment factors (6MWD, SVO2 and treprostinil dose) were predictors of survival in this study and may be used to aid in treatment optimization.